维普中文期刊产品整合服务
3篇 您的检索式:作者名="Mengdan YU"
    题名 作者 年代 出处 被引量
1cFLIPS regulates alternative NLRP3 inflammasome activation in human monocytes显示文摘The innate immune responses,including inflammasome activation,are paramount for host defense against pathogen infection.In contrast to canonical and noncanonical inflammasome activation,in this study,heat-killed gram-negative bacteria(HK bacteria)were identified as single-step stimulators of the NLRP3 inflammasome in human monocytes,and they caused a moderate amount of IL-1βto be released from cells.Time course experiments showed that this alternative inflammasome response was finished within a few hours.Further analysis showed that the intrinsically limited NLRP3 inflammasome activation response was due to the negative regulation of caspase-8 by the short isoform of cFLIP(cFLIPs),which was activated by NF-κB.In contrast,overexpressed cFLIPS,but not overexpressed cFLIPL,inhibited the activation of caspase-8 and the release of IL-1βin response to HK bacteria infection in human monocytes.Furthermore,we demonstrated that TAK1 activity mediated the expression of cFLIPs and was upstream and essential for the caspase-8 cleavage induced by HK bacteria in human monocytes.The functional specificity of cFLIPs and TAK1 revealed unique responses of human monocytes to a noninvasive pathogen,providing novel insights into an alternative regulatory pathway of NLRP3 inflammasome activation.Yuhui Gao Shi Yu Mengdan Chen Xun Wang Lei Pan Bin Wei Guangxun Meng 2023Cellular & Molecular Immunology2023,20,10:0
2BCAT1 promotes lung adenocarcinoma progression through enhanced mitochondrial function and NF-κB pathway activation显示文摘Lung cancer is one of the most prevalent and malignant cancers,among which lung adenocarcinoma(LUAD)accounts for the majority and remains a major cause of cancer-related mortality worldwide(Cui et al.,2019).Despite the growing intensity of research on the pathobiology and progression of lung cancer and the fact that many genes have been identified as potential drivers and targets for therapy(Luo et al.,2019;Zhang et al.,2019),the treatment and prognosis of lung cancer patients have hardly improved.Therefore,this study aimed to investigate the precise mechanism of lung cancer development and explore efficient diagnostic and therapeutic methods for clinical treatment.Mengdan YU Qianwei ZHAO Jinxia LI Fang XU Zhibiao ZHANG Yixian LIU Liping DAI Bingxia ZHANG Jianying ZHANG Jintao ZHANG 2022Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2022,23,9:0
3TAK1 Deficiency in Macrophages Increases Host Susceptibility to Leishmania Infection显示文摘Leishmania parasites mainly infect macrophages and may cause severe immunopathologies in their host,which are called leishman-iases.In the current work,we infected human and mouse macrophages in vitro with Leishmania major,an etiological agent of cu-taneous leishmaniasis,and found that inhibition or deletion of the transforming growth factorβ–activated kinase 1(TAK1)gene re-sulted in increased parasite loads.In vivo,following a challenge with L.major,mice with a macrophage-specific deletion of TAK1 showed increased clinical signs and higher parasite loads compared with wild-type controls.TAK1 deficiency in mouse macro-phages led to biased Th2 cell responses during the acute stage of infection,characterized by a decrease in interferon-γexpression,and increased expression of IL-4,IL-5 and IL-10.Finally,we found that,in the late stage of L.major infection,excessive Th2-related cytokines led to high arginase 1 expression in mouse tissues and a significant reduction of NO production both locally and system-ically,resulting in compromised control of Leishmania.These findings suggest that TAK1 plays a vital role in host resistance to Leish-mania infection.Xiankai Cao Kossiwa C.Kokou Shi Yu Mengdan Chen Junling Niu HervéLecoeur Eric Prina Gerald F.Späth Guangxun Meng 2023Infectious Microbes & Diseases2023,5,3:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费